Merck & Co. Inc. (MRK), said Wednesday that V114, the company's investigational 15-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of invasive pneumococcal disease or IPD caused by the vaccine serotypes in pediatric patients 6 weeks to 18 years of age.
from RTT - Biotech http://bit.ly/2TnTzXW
via IFTTT
No comments:
Post a Comment